{"id":980695,"date":"2026-07-10T09:40:03","date_gmt":"2026-07-10T13:40:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ions-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-ionis-pharmaceuticals\/"},"modified":"2026-07-10T09:40:03","modified_gmt":"2026-07-10T13:40:03","slug":"ions-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-ionis-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ions-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-ionis-pharmaceuticals\/","title":{"rendered":"IONS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ionis Pharmaceuticals"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Ionis Pharmaceuticals lost more than 20% before the market opened — a decline of nearly $17 — after its Phase-3 CARDIO-TTRansform trial missed its primary endpoint. SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of IONS investors.<\/i>\n <\/p>\n

\n NEW YORK<\/span>, July 10, 2026<\/span> \/PRNewswire\/ — Shares of Ionis Pharmaceuticals (NASDAQ: IONS) dropped more than 20% pre-market on July 9, 2026, after the Company announced that its late-stage Phase-3 CARDIO-TTRansform trial failed to meet its primary endpoint. If you suffered a loss on your Ionis investment, you are encouraged to submit your information here<\/a>. You may also contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com<\/a> or by telephone at (888) SueWallSt.<\/p>\n

\n

\n \"SueWallSt.com\"\n <\/p>\n<\/p><\/div>\n

The CARDIO-TTRansform trial, partnered with AstraZeneca, was designed to reduce the combined rate of cardiovascular death and recurrent cardiovascular events in patients with transthyretin-mediated amyloid cardiomyopathy. On July 9, 2026, the Company disclosed that the trial did not achieve that primary endpoint.<\/p>\n

The market reaction was swift and the negative readout drove an immediate pre-market decline. The investigation concerns whether Ionis Pharmaceuticals made statements to investors about the CARDIO-TTRansform program that are being examined in light of the July 9, 2026 outcome and the resulting share-price decline.<\/p>\n

Investors who purchased IONS shares and lost money are encouraged to click here to learn more about the investigation<\/a>. You may also contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com<\/a> or by telephone at (888) SueWallSt.<\/p>\n

\n WHY SUEWALLST<\/b>: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.<\/p>\n

\n Frequently Asked Questions About the IONS Investigation<\/b>\n <\/p>\n

\n Q: How much did IONS stock drop?<\/b> A: Shares fell approximately 20% before the market opened but following the Company’s disclosure that that its Phase-3 CARDIO-TTRansform trial failed to meet its primary endpoint. Investors who purchased shares and suffered losses may be eligible to seek recovery.<\/p>\n

\n Q: What is the IONS investigation about?<\/b> A: A securities investigation is pending concerning Ionis Pharmaceuticals (NASDAQ: IONS) regarding potentially materially false or misleading statements. Shares fell more than 20% after the Company disclosed the failure of its Phase-3 CARDIO-TTRansform trial, causing losses for shareholders.<\/p>\n

\n Q: Who is eligible to participate in the IONS investigation?<\/b> A: Investors who purchased IONS stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses — not on whether you still hold the shares.<\/p>\n

\n Q: What if I already sold my IONS shares — can I still recover losses?<\/b> A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought IONS and sold at a loss may still participate in the investigation.<\/p>\n

\n Q: What if my IONS losses are small — is it still worth contacting a lawyer?<\/b> A: Yes. There is no minimum loss amount required to participate in the investigation.<\/p>\n

\n Q: What does it cost me to participate?<\/b> A: There is no upfront cost to participate. Securities investigations and any resulting actions are generally handled on a contingency basis. No upfront fees, no retainer, and no out-of-pocket costs.<\/p>\n

\n Q: What do IONS investors need to do right now?<\/b> A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact SueWallSt, a brand of Levi & Korsinsky LLP, for a no-cost, no-obligation evaluation at jlevi@levikorsinsky.com<\/a> or (212) 363-7500. No immediate action is required to remain eligible to participate in the investigation.<\/p>\n

\n Q: Do I need to go to court or give testimony?<\/b> A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.<\/p>\n

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@SueWallSt.com<\/a>
Tel: (888)\u00a0SueWallSt
Fax: (212) 363-7171<\/p>\n

Attorney Advertising. Prior results do not guarantee similar outcomes.<\/p>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/ions-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-ionis-pharmaceuticals-302822388.html<\/a><\/p>\n

SOURCE SueWallSt.com<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire Ionis Pharmaceuticals lost more than 20% before the market opened — a decline of nearly $17 — after its Phase-3 CARDIO-TTRansform trial missed its primary endpoint. SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of IONS investors. NEW YORK, July 10, 2026 \/PRNewswire\/ — Shares of Ionis Pharmaceuticals (NASDAQ: IONS) dropped more than 20% pre-market on July 9, 2026, after the Company announced that its late-stage Phase-3 CARDIO-TTRansform trial failed to meet its primary endpoint. If you suffered a loss on your Ionis investment, you are encouraged to submit your information here. You may also contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com or by telephone at (888) SueWallSt. The CARDIO-TTRansform … <\/p>\n

Continue reading “IONS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ionis Pharmaceuticals”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-980695","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nIONS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ionis Pharmaceuticals - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ions-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-ionis-pharmaceuticals\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IONS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ionis Pharmaceuticals - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire Ionis Pharmaceuticals lost more than 20% before the market opened — a decline of nearly $17 — after its Phase-3 CARDIO-TTRansform trial missed its primary endpoint. SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of IONS investors. NEW YORK, July 10, 2026 \/PRNewswire\/ — Shares of Ionis Pharmaceuticals (NASDAQ: IONS) dropped more than 20% pre-market on July 9, 2026, after the Company announced that its late-stage Phase-3 CARDIO-TTRansform trial failed to meet its primary endpoint. If you suffered a loss on your Ionis investment, you are encouraged to submit your information here. You may also contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com or by telephone at (888) SueWallSt. The CARDIO-TTRansform … Continue reading "IONS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ionis Pharmaceuticals"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ions-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-ionis-pharmaceuticals\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-10T13:40:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mmx.prnewswire.com\/media\/MS1812443\/suewallst-logo-1-Logo.jpg?id=OA2757962\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ions-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-ionis-pharmaceuticals\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ions-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-ionis-pharmaceuticals\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"IONS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ionis Pharmaceuticals\",\"datePublished\":\"2026-07-10T13:40:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ions-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-ionis-pharmaceuticals\\\/\"},\"wordCount\":736,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ions-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-ionis-pharmaceuticals\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1812443\\\/suewallst-logo-1-Logo.jpg?id=OA2757962\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ions-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-ionis-pharmaceuticals\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ions-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-ionis-pharmaceuticals\\\/\",\"name\":\"IONS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ionis Pharmaceuticals - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ions-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-ionis-pharmaceuticals\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ions-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-ionis-pharmaceuticals\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1812443\\\/suewallst-logo-1-Logo.jpg?id=OA2757962\",\"datePublished\":\"2026-07-10T13:40:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ions-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-ionis-pharmaceuticals\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ions-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-ionis-pharmaceuticals\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ions-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-ionis-pharmaceuticals\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1812443\\\/suewallst-logo-1-Logo.jpg?id=OA2757962\",\"contentUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1812443\\\/suewallst-logo-1-Logo.jpg?id=OA2757962\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ions-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-ionis-pharmaceuticals\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IONS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ionis Pharmaceuticals\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IONS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ionis Pharmaceuticals - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ions-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-ionis-pharmaceuticals\/","og_locale":"en_US","og_type":"article","og_title":"IONS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ionis Pharmaceuticals - Market Newsdesk","og_description":"PR Newswire Ionis Pharmaceuticals lost more than 20% before the market opened — a decline of nearly $17 — after its Phase-3 CARDIO-TTRansform trial missed its primary endpoint. SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of IONS investors. NEW YORK, July 10, 2026 \/PRNewswire\/ — Shares of Ionis Pharmaceuticals (NASDAQ: IONS) dropped more than 20% pre-market on July 9, 2026, after the Company announced that its late-stage Phase-3 CARDIO-TTRansform trial failed to meet its primary endpoint. If you suffered a loss on your Ionis investment, you are encouraged to submit your information here. You may also contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com or by telephone at (888) SueWallSt. The CARDIO-TTRansform … Continue reading \"IONS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ionis Pharmaceuticals\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ions-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-ionis-pharmaceuticals\/","og_site_name":"Market Newsdesk","article_published_time":"2026-07-10T13:40:03+00:00","og_image":[{"url":"https:\/\/mmx.prnewswire.com\/media\/MS1812443\/suewallst-logo-1-Logo.jpg?id=OA2757962","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ions-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-ionis-pharmaceuticals\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ions-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-ionis-pharmaceuticals\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"IONS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ionis Pharmaceuticals","datePublished":"2026-07-10T13:40:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ions-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-ionis-pharmaceuticals\/"},"wordCount":736,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ions-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-ionis-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS1812443\/suewallst-logo-1-Logo.jpg?id=OA2757962","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ions-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-ionis-pharmaceuticals\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ions-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-ionis-pharmaceuticals\/","name":"IONS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ionis Pharmaceuticals - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ions-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-ionis-pharmaceuticals\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ions-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-ionis-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS1812443\/suewallst-logo-1-Logo.jpg?id=OA2757962","datePublished":"2026-07-10T13:40:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ions-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-ionis-pharmaceuticals\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ions-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-ionis-pharmaceuticals\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ions-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-ionis-pharmaceuticals\/#primaryimage","url":"https:\/\/mmx.prnewswire.com\/media\/MS1812443\/suewallst-logo-1-Logo.jpg?id=OA2757962","contentUrl":"https:\/\/mmx.prnewswire.com\/media\/MS1812443\/suewallst-logo-1-Logo.jpg?id=OA2757962"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ions-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-ionis-pharmaceuticals\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"IONS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ionis Pharmaceuticals"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/980695","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=980695"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/980695\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=980695"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=980695"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=980695"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}